FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119379728> ?p ?o ?g. }

• W3119379728 abstract "Abstract Background The restoration of immune responses is thought as a complementary approach to the nucleos(t)ide analogue (NUC) therapy of chronic HBV infection. The antiviral immunity is negatively regulated by the programmed cell death-1/programmed death ligand-1 (PD-1/PD-L1) axis. Here, the soluble form of PD-L1 (sPD-L1) that represents the amount of PD-L1 expression cells was used as an indicator to investigate the involvement of this axis in chronic HBV infection, especially in the setting of NUC therapy. Methods A total of 273 adult patients with chronic HBV infection, regardless of the treatment, and 86 healthy controls were consecutively enrolled. Serum sPD-L1 was measured using an ELISA assay. Its correlations with clinical/virological characteristics were analyzed. Results Serum sPD-L1 levels in patients with chronic HBV infection (median 425.2 IQR 245.8-558.6 pg/mL) were significantly higher than those in healthy controls (median 81.69 IQR 54.62-121.1 pg/mL). Among patients at various disease phases, those with immune-tolerant CHB had the lowest sPD-L1 levels (median 205.3 IQR 92.27-340.7 pg/mL). These results indicated that serum sPD-L1 was significantly increased in a manner of two steps from health to infection and from immunotolerance to immunoactivation in chronic HBV infection. Furthermore, the serum sPD-L1 in immune-active CHB was correlated with HBsAg positively, HBV DNA negatively and liver damage marginally. Interestingly, the increased serum sPD-L1 levels were strongly associated with the treatment of NUCs, especially in HBeAg-positive immune-active CHB. Conclusions Serum sPD-L1 might be a meaningful indicator to monitor the immune status and disease progression in chronic HBV infection. The correlations of the increased sPD-L1 with HBsAg and NUC treatment suggest that the activated PD-1/PD-L1 axis may explain the rarity of HBsAg seroconversion of NUC therapy and the clinically available checkpoint inhibitors may serve as partners for NUCs to improve their anti-HBV efficacy in the future" @default.
• W3119379728 created "2021-01-18" @default.
• W3119379728 creator A5001551737 @default.
• W3119379728 creator A5003823004 @default.
• W3119379728 creator A5006917023 @default.
• W3119379728 creator A5078798578 @default.
• W3119379728 creator A5080599082 @default.
• W3119379728 creator A5084352560 @default.
• W3119379728 date "2020-03-18" @default.
• W3119379728 modified "2023-09-25" @default.
• W3119379728 title "Serum soluble programmed death ligand-1 is correlated with HBsAg level and nucleos(t)ide analogue therapy in chronic hepatitis B" @default.
• W3119379728 cites W1910012553 @default.
• W3119379728 cites W1992569798 @default.
• W3119379728 cites W2080010723 @default.
• W3119379728 cites W2590941489 @default.
• W3119379728 cites W2639316115 @default.
• W3119379728 cites W2755711848 @default.
• W3119379728 cites W2781100796 @default.
• W3119379728 cites W2791839818 @default.
• W3119379728 cites W2794634849 @default.
• W3119379728 cites W2893024156 @default.
• W3119379728 cites W2904463945 @default.
• W3119379728 cites W2951931980 @default.
• W3119379728 cites W2962219096 @default.
• W3119379728 cites W2966340800 @default.
• W3119379728 cites W2981190229 @default.
• W3119379728 doi "https://doi.org/10.21203/rs.3.rs-17628/v1" @default.
• W3119379728 hasPublicationYear "2020" @default.
• W3119379728 type Work @default.
• W3119379728 sameAs 3119379728 @default.
• W3119379728 citedByCount "0" @default.
• W3119379728 crossrefType "posted-content" @default.
• W3119379728 hasAuthorship W3119379728A5001551737 @default.
• W3119379728 hasAuthorship W3119379728A5003823004 @default.
• W3119379728 hasAuthorship W3119379728A5006917023 @default.
• W3119379728 hasAuthorship W3119379728A5078798578 @default.
• W3119379728 hasAuthorship W3119379728A5080599082 @default.
• W3119379728 hasAuthorship W3119379728A5084352560 @default.
• W3119379728 hasBestOaLocation W31193797281 @default.
• W3119379728 hasConcept C126322002 @default.
• W3119379728 hasConcept C203014093 @default.
• W3119379728 hasConcept C2522874641 @default.
• W3119379728 hasConcept C2777382497 @default.
• W3119379728 hasConcept C2777410769 @default.
• W3119379728 hasConcept C2779341262 @default.
• W3119379728 hasConcept C2780593183 @default.
• W3119379728 hasConcept C3020491458 @default.
• W3119379728 hasConcept C71924100 @default.
• W3119379728 hasConcept C8891405 @default.
• W3119379728 hasConcept C90924648 @default.
• W3119379728 hasConceptScore W3119379728C126322002 @default.
• W3119379728 hasConceptScore W3119379728C203014093 @default.
• W3119379728 hasConceptScore W3119379728C2522874641 @default.
• W3119379728 hasConceptScore W3119379728C2777382497 @default.
• W3119379728 hasConceptScore W3119379728C2777410769 @default.
• W3119379728 hasConceptScore W3119379728C2779341262 @default.
• W3119379728 hasConceptScore W3119379728C2780593183 @default.
• W3119379728 hasConceptScore W3119379728C3020491458 @default.
• W3119379728 hasConceptScore W3119379728C71924100 @default.
• W3119379728 hasConceptScore W3119379728C8891405 @default.
• W3119379728 hasConceptScore W3119379728C90924648 @default.
• W3119379728 hasLocation W31193797281 @default.
• W3119379728 hasOpenAccess W3119379728 @default.
• W3119379728 hasPrimaryLocation W31193797281 @default.
• W3119379728 hasRelatedWork W2040973434 @default.
• W3119379728 hasRelatedWork W2057948995 @default.
• W3119379728 hasRelatedWork W2373048719 @default.
• W3119379728 hasRelatedWork W2377909279 @default.
• W3119379728 hasRelatedWork W2996529356 @default.
• W3119379728 hasRelatedWork W3017822181 @default.
• W3119379728 hasRelatedWork W3032210197 @default.
• W3119379728 hasRelatedWork W4295886166 @default.
• W3119379728 hasRelatedWork W573847062 @default.
• W3119379728 hasRelatedWork W4290227086 @default.
• W3119379728 isParatext "false" @default.
• W3119379728 isRetracted "false" @default.
• W3119379728 magId "3119379728" @default.
• W3119379728 workType "article" @default.